Use of Tranexamic Acid in Reduction Mammoplasty

PHASE4CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

July 13, 2022

Study Completion Date

July 13, 2022

Conditions
Hematoma PostoperativeVenous Thromboembolism
Interventions
DRUG

Tranexamic acid

Topical tranexamic acid (1000mg) will be administered to the raw surface of the breast prior to closure of the incisions.

OTHER

Placebo (topical saline)

The untreated breast will receive topical saline.

Trial Locations (1)

10461

Montefiore Medical Center Hutchinson Metro Center Campus, The Bronx

All Listed Sponsors
collaborator

The Plastic Surgery Foundation

OTHER

lead

Montefiore Medical Center

OTHER

NCT04947514 - Use of Tranexamic Acid in Reduction Mammoplasty | Biotech Hunter | Biotech Hunter